18 April 2017 - Sarilumab was approved by Health Canada on 12 Jan 2017 for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more biologic or non-biologic disease-modifying anti-rheumatic drugs.

The CADTH CDEC had recommended that sarilumab be reimbursed for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more biologic or non- biologic disease-modifying anti-rheumatic drug (DMARD), as monotherapy or in combination with methotrexate or another non-biologic DMARD, if the following conditions are met:

Conditions:

• Reimburse in a similar manner to other biologics for the treatment of moderately to severely active rheumatoid arthritis.
  
• The drug plan cost of treatment with sarilumab should not exceed the drug plan cost of treatment with the least costly alternative biologic.
  

Read CADTH outcome for sarilumab